X. Xiong, L. W. Zheng, Y. Ding, Y. F. Chen, Y. W. Cai, L. P. Wang. Breast cancer: pathogenesis and treatments. Signal Transduction and Targeted Therapy 2025; 10:

N. Altriche, S. Gallant, T. N. Augustine, K. R. Xulu. Navigating the Intricacies of Tumor Heterogeneity: An Insight into Potential Prognostic Breast Cancer Biomarkers. Biomarker Insights 2024; 19:

C. N. Baxevanis, S. P. Fortis, S. A. Perez. The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies. Seminars in Cancer Biology 2021; 72: 76-89.

C. Guillerey. NK Cells in the Tumor Microenvironment. Advances in Experimental Medicine and Biology 2020; : 69-90.

R. Kim, M. Emi, K. Tanabe. Cancer immunoediting from immune surveillance to immune escape. Immunology 2007; 121(1): 1-14.

M. Wang, C. Zhang, Y. Song, Z. Wang, Y. Wang, F. Luo. Mechanism of immune evasion in breast cancer. OncoTargets and Therapy 2017; 10: 1561-1573.

H. Zhao, L. Wu, G. Yan, Y. Chen, M. Zhou, Y. Wu. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduction and Targeted Therapy 2021; 6:

M. D. Vesely, R. D. Schreiber. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Annals of the New York Academy of Sciences 2013; 1284(1): 1-5.

T. Carré, J. Thiery, B. Janji, S. Terry, G. Gros, G. Meurice. Selection of tumor‑resistant variants following sustained natural killer cell‑mediated immune stress. Oncology Reports 2021; 45(2): 582-594.

D. C. Hinshaw, L. A. Shevde. The tumor microenvironment innately modulates cancer progression. Cancer Research 2019; 79: 4557-4567.

Y. Yu. The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy. Cancers 2023; 15:

N. Luo, M. J. Nixon, P. I. Gonzalez-Ericsson, V. Sanchez, S. R. Opalenik, H. Li. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nature Communications 2018; 9(1): 248.

M. Shen, H. A. Smith, Y. Wei, Y. Z. Jiang, S. Zhao, N. Wang. Pharmacological disruption of the MTDH-SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer. Nature Cancer 2022; 3(1): 60-74.

D. V. Rozanov, N. D. Rozanov, K. E. Chiotti, A. Reddy, P. A. Wilmarth, L. L. David. MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection. Journal of Proteomics 2018; 176: 13-23.

S. Chen, H. Zhu, Y. Jounaidi. Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization. Signal Transduction and Targeted Therapy 2024; 9:

R. C. Rees, S. Mian. Selective MHC expression in tumours modulates adaptive and innate antitumour responses. Cancer Immunology, Immunotherapy 1999; 48(7): 374-381.

A. A. Barkal, K. Weiskopf, K. S. Kao, S. R. Gordon, B. Rosental, Y. Y. Yiu. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nature Immunology 2018; 19(1): 76-84.

B. C. Taylor, X. Sun, P. I. Gonzalez-Ericsson, V. Sanchez, M. E. Sanders, E. C. Wescott. NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer. Cancer Discovery 2024; 14(2): 290-307.

A. M. Cornel, I. L. Mimpen, S. Nierzeks. MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy. Cancers 2020; 12(7): 1760.

A. M. Cornel, I. L. Mimpen, S. Nierkens. MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy. Cancers 2020; 12(7): 1760.

N. Luo, M. J. Nixon, P. I. Gonzalez-Ericsson, V. Sanchez, S. R. Opalenik, H. Li. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nature Communications 2018; 9(1): 248.

E. Fonsatti, H. J. Nicolay, L. Sigalotti, L. Calabrò, L. Pezzani, F. Colizzi. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2′-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clinical Cancer Research 2007; 13(11): 3333-8.

A. Serrano, S. Tanzarella, I. Lionello, R. Mendez, C. Traversari, F. Ruiz-Cabello. Reexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatment. International Journal of Cancer 2001; 94(2): 243-51.

L. Spel, J. Nieuwenhuis, R. Haarsma, E. Stickel, O. B. Bleijerveld, M. Altelaar. Nedd4-Binding Protein 1 and TNFAIP3-Interacting Protein 1 Control MHC-1 Display in Neuroblastoma. Cancer Research 2018; 78(23): 6621-31.

E. Mamessier, A. Sylvain, M. L. Thibult, G. Houvenaeghel, J. Jacquemier, R. Castellano. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. Journal of Clinical Investigation 2011; 121(9): 3609-3622.

B. Cózar, M. Greppi, S. Carpentier, E. Narni-Mancinelli, L. Chiossone, E. Vivier. Tumor-infiltrating natural killer cells. Cancer Discovery 2021; 11: 34-44.

L. Amo, E. Tamayo-Orbegozo, N. Maruri, A. Buqué, M. Solaun, M. Riñón. Podocalyxin-like protein 1 functions as an immunomodulatory molecule in breast cancer cells. Cancer Letters 2015; 368(1): 26-35.

E. Arianfar, S. Shahgordi, A. Memarian. Natural Killer Cell Defects in Breast Cancer: A Key Pathway for Tumor Evasion. International Reviews of Immunology 2021; 40: 197-216.

J. Zhang, F. Guo, L. Li, S. Zhang, Y. Wang. Immune evasion and therapeutic opportunities based on natural killer cells. Chinese Journal of Cancer Research 2023; 35(3): 283-298.

M. Abd Hamid, R. Z. Wang, X. Yao, P. Fan, X. Li, X. M. Chang. Enriched HLA-E and CD94/NKG2A Interaction Limits Antitumor CD8+ Tumor-Infiltrating T Lymphocyte Responses. Cancer Immunology Research 2019; 7(8): 1293-1306.

X. Liu, J. Song, H. Zhang, X. Liu, F. Zuo, Y. Zhao. Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell 2023; 41(2): 272-287.e9.

R. Okita, D. Mougiakakos, T. Ando, Y. Mao, D. Sarhan, E. Wennberg. HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines. Journal of Immunology 2012; 188(5): 2136-2145.

Z. Madjd, I. Spendlove, R. Moss, S. Bevin, S. E. Pinder, N. F. Watson. Upregulation of MICA on high-grade invasive operable breast carcinoma. Cancer Immunology 2007; 7:

J. Shen, J. Pan, C. Du, W. Si, M. Yao, L. Xu. Silencing NKG2D ligand-targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancer. Cell Death and Disease 2017; 8(4): e2740.

J. G. Fisher, A. D. P. Doyle, L. V. Graham, S. I. Khakoo, M. D. Blunt. Disruption of the NKG2A:HLA-E immune checkpoint axis to enhance NK cell activation against cancer. Vaccines 2022; 10: